In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, ...

(Alliance News) - Sareum Holdings PLC on Tuesday said a biopharma company in the US has served notice to terminate a development & commercialisation licence for Sareum's SRA737 clinical-stage cancer ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed ...

Sareum Holdings ( (GB:SAR) ) has shared an update.